Updates in Using TAVR for Treating Aortic Stenosis, with Linda Gillam, MD, MPH
Linda Gillam, MD, MPH, discusses updates in the management of aortic stenosis, with a focus on use of TAVR.
If Successful, Inclisiran Primary Prevention Trial Could Expand Patient Population by More than 22 Million
Rahul Aggarwal, MD, discusses how the VICTORION-1 PREVENT trial eligibility criteria apply to the general US population.
HCPLive Five at ESC 2024
Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key updates from the European Society of Cardiology (ESC) Congress 2024.
Deepak Bhatt, MD, MPH, MBA: SGLT2 Offers Kidney Protective Benefit in Post-MI Population
Deepak Bhatt, MD, MPH, MBA, discusses the results of a prespecified analysis of the EMPACT-MI trial examining the effect across the spectrum of baseline kidney function.
Study Finds Traditional Risk Scores Miss Most Patients at Risk of First Heart Attack
New study finds ASCVD risk score often misses at-risk patients for first acute coronary syndrome, highlighting need for better prediction methods.
ESC Congress Recap: High-Impact Clinical Trials, with Deepak Bhatt, MD, MPH, MBA
Deepak Bhatt, MD, MPH, MBA, discusses a group of 4 high-impact studies from ESC Congress 2024: FINEARTS-HF, ABYSS, RESHAPE-HF2, and SHAM-PVI.
Aficamten in the Spotlight at ESC Congress, with Ahmad Masri, MD, MS
Ahmad Masri, MD, MS, highlights a trio of studies from ESC Congress 2024 examining use of aficamten in hypertrophic cardiomyopathy.
SEQUOIA-HCM Substudy Details Effects of Aficamten on Cardiac Structure and Remodeling
Ahmad Masri, MD, MS, discusses the results of a SEQUOIA-HCM substudy leveraging cardiac magnetic resonance to assess structural changes associated with aficamten use in HCM.
ESC Congress Study Highlights Safety of Aficamten in Hypertrophic Cardiomyopathy
Ahmad Masri, MD, MS, discusses an integrated safety analysis of aficamten using data from 3 clinical trials.
Siddharth Patel, MD, MPH: Abelacimab Could Help Reduce Procedure-Related Bleeding
Siddharth Patel, MD, MPH, discusses how an AZALEA-TIMI 71 analysis presented at ESC Congress 2024.
EMPACT-MI Kidney: SGLT2 Initiation Can Preserve Kidney Function in Post-MI Population
EMPACT-MI study shows empagliflozin is safe post-acute MI and reduces heart failure events, with kidney protection across kidney function levels.
PALISADE: Plozasiran Offers Hope for Treating Familial Chylomicronemia Syndrome
ESC 2024: Phase 3 PALISADE trial shows plozasiran significantly lowers triglycerides and pancreatitis risk in FCS; NDA planned by year-end.
Kausik Ray, MD, MPhil: INTERASPIRE and the Expanding Knowledge Base for Lipoprotein(a)
Kausik Ray, MD, MPhil, discusses the results of the INTERASPIRE study and how it improves our understanding of the effects of elevated Lp(a).
Long-Term Data from ESC 2024 Reinforces Safety, Efficacy Profile of Mavacamten in oHCM
MAVA-LTE trial data show mavacamten's sustained benefits in symptomatic obstructive HCM, with long-term improvements in LVOT, NT-proBNP, and quality of life.
Brendon Neuen, MBBS, PhD: Expanding Evidence of Combination Therapy with GLP-1 RAs and SGLT2 Inhibitors
A meta-analysis shows GLP-1 RAs and SGLT2 inhibitors offer distinct cardiovascular and kidney benefits in type 2 diabetes.
OCEANIC-AF: Asundexian Patients Have Nearly 4x Stroke, Embolism Risk vs Apixaban Patients
Asundexian failed to prove noninferiority to apixaban for its primary efficacy outcome in the phase 3 OCEANIC-AF trial.
Rahul Aggarwal, MD: Sotagliflozin Benefit Grows with Increasing Diabetes Duration
Rahul Aggarwal, MD, discusses the findings of a SCORED analysis examining sotagliflozin's effects based on diabetes duration.
FLOW: Semgalutide Provides Consistent CV Benefit Across Spectrum of Kidney Disease
Kenneth Mahaffey, MD, discusses FLOW trial data showing semaglutide improves cardiovascular outcomes in patients with type 2 diabetes, regardless of CKD severity.
M-TEER Reduces Cardiovascular Risk, Improves Quality of Life in HF with Mitral Regurgitation
RESHAPE-HF2 shows mitral transcatheter edge-to-edge repair (M-TEER) reduces heart failure hospitalizations and improves quality of life vs optimal medical therapy alone.
Single Blood Test Could Predict Cardiovascular, Stroke Risk in Women for Up to 30 Years
A single blood test using hsCRP, LDL-C, and Lp(a) levels can predict cardiovascular risk for women up to 30 years, emphasizing personalized care.
In Women, History of Cancer Linked to Subclinical Atherosclerosis
Sara Diaz Saravia, MD, discusses a study from ESC Congress 2024 examining the utility of cancer history in women as a predictor of subclinical atherosclerosis.
Common Pitfalls to Avoid When Interpreting Clinical Trials, with Deepak Bhatt, MD, MPH, MBA
Deepak Bhatt, MD, MPH, MBA, discusses common pitfalls for clinicians when interpreting trial data based on a presentation he led at ESC Congress 2024.
Endometriosis Linked to Elevated Risk of Heart Attack, Stroke in Women
Women with endometriosis experienced a 20% greater risk of cardiac outcomes compared with women without endometriosis.
STOP-or-NOT: No Benefit to Discontinuing RASi Prior to Major Surgery
The STOP-or-NOT trial found similar outcomes for continuation or discontinuation of RAS inhibitors before noncardiac surgery, supporting individualized decision-making.
Catching Up on Sleep on Weekends Links to 20% Lower Risk of Developing Heart Disease
People with the most weekend catch-up sleep had a 20% lower risk of heart disease, especially those who were sleep-deprived during the week.
Vutrisiran Reduces Cardiovascular Risk, Improves Quality of Life in ATTR-CM
HELIOS-B trial shows vutrisiran reduces all-cause mortality and CV events in ATTR-CM, with benefits consistent regardless of tafamidis use.
ABYSS Trial: No Difference in Outcomes Continuing or Stopping Beta-Blockers Following MI
The ABYSS trial suggests no clear benefit of continuing beta-blockers post-MI in patients with preserved LVEF, echoing REDUCE-AMI findings.
Smoking Cessation Halves MACE Risk, Reduction Offers Little Protection
Patients with stable CAD who quit smoking reduced the risk of a major event by nearly 50%, while a reduction in smoking habits demonstrated minimal effects.
ESC Congress 2024 Lipidology Preview, with Professor Kausik Ray
Kausik Ray, MD, discusses what trials and new data in lipidology he is most looking forward to from the upcoming ESC Congress.
ESC Congress 2024 Clinical Trials to Watch, with Deepak Bhatt, MD, MPH, MBA
Deepak Bhatt, MD, MPH, MBA, discusses 7 trials to watch from hotline or late-breaking sessions at the upcoming European Society of Cardiology Congress 2024.
